Thermo Fisher Scientific opened its Cryo‑EM Drug Discovery Center (CDDC) in the Oyster Point area of South San Francisco on March 5 2026, giving pharmaceutical and biotechnology companies direct, hands‑on access to advanced cryo‑electron microscopy equipment and expertise.
The center builds on Thermo Fisher’s partnership with the UK Pharmaceutical Cryo‑EM Consortium, a collaboration that has accelerated industrial adoption of cryo‑EM since 2016. By providing a shared, high‑resolution imaging environment, the CDDC is positioned to speed the discovery of structure‑based therapeutics, a field that has seen a surge in demand as companies seek faster, more precise drug design.
Thermo Fisher’s recent financial performance underscores the strategic importance of the new center. In Q4 2025 the company reported revenue of $12.21 billion, up 7% from the prior year, and adjusted earnings per share of $6.57, beating consensus estimates of $6.45 by $0.12. The company forecast 2026 revenue of $46.3 billion to $47.2 billion and adjusted EPS of $24.22 to $24.80, reflecting confidence in continued growth and margin stability.
The CDDC aligns with Thermo Fisher’s Life Sciences Solutions segment, which focuses on providing integrated research tools and services. By expanding its cryo‑EM capabilities, the company is reinforcing its position as a one‑stop shop for life‑sciences R&D, potentially increasing revenue from high‑margin service contracts and deepening customer relationships across its core segments.
Glyn Davies, president of Materials & Structural Analysis, said, “At Thermo Fisher, so much of what we do is grounded in helping our customers perform research that brings life‑saving medicines to patients faster and more effectively. The opening of our Cryo‑EM Drug Discovery Center creates a collaborative environment where scientists can directly harness the power of Cryo‑EM to better understand disease at the molecular level and accelerate therapeutic development.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.